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Abstract
Introduction
Healthcare decision-makers are increasingly expected to balance increasing demand for
health services with a finite budget. The role of economic evaluation in healthcare is increas-
ing and this research provides decision-makers with new information about the manage-
ment of Clostridium difficile infection, from an economic perspective.
Methods
A model-based economic evaluation was undertaken to identify the most cost-effective
healthcare intervention relating to the reduction of Clostridium difficile transmission. Efficacy
evidence was synthesised from the literature and was used to inform the effectiveness of
both bundled approaches and stand-alone interventions, where appropriate intervention
combinations were coupled together. Changes in health outcomes were estimated by com-
bining information about intervention effectiveness and its subsequent impact on quality of
life.
Results
A bundled approach of improving hand hygiene and environmental cleaning produces the
best combination of increased health benefits and cost-savings. It has the highest mean net
monetary benefit when compared to all other interventions. This intervention remains the
optimal decision under different clinical circumstances, such as when mortality rate and
patient length of stay are increased. Bundled interventions offered the best opportunity for
health improvements.
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Conclusion
These findings provide healthcare decision-makers with novel information about the alloca-
tion of scarce resources relating to Clostridium difficile. If investments are not made in inter-
ventions that clearly yield gains in health outcomes, the allocation and use of scarce
healthcare resources is inappropriate and improvements in health outcomes will be forgone.
Introduction
Clostridium difficile (C. difficile) is the most common cause of hospital-acquired infectious
diarrhoea and represents a significant challenge for health services [1]. It is primarily transmit-
ted via the fecal-oral pathway, through ingestion of bacterial spores [2]. The majority of cases
follow the use of antibiotics, which disturb the resident gut microflora [2]. Other risk factors
include advanced age, frequent admission to hospital and comorbidity [3]. Infection can cause
a range of clinical symptoms, including severe diarrhoea, pseudomembranous colitis, and in
extreme cases, death [4]. It is the most common cause of infectious, hospital-acquired diar-
rhoea and is reported to be responsible for 15–25% of antibiotic associated diarrhoea [2; 5]
Following the spread of hypervirulent strains, most notably ribotype 027, an increase in severe
cases has been documented in studies from the UK, Europe and North America [6]. Recurrent
infection, where patients are treated for their initial infection then suffer either a relapse or
reinfection, is a common feature of the disease [7]. Recurrence rates have been reported to be
25% of all cases (range 6–42%), increasing patient vulnerability and debilitation while incur-
ring economic costs through increased patient length of stay and hospitilisation [8]. Informa-
tion on the attributable cost of C. difficile infection (CDI) varies, with estimates of primary
infection costs ranging from USD $3,400–$16,300 per case [9] and recurrent infection between
USD $13,700–$18,000 [10]. CDI-attributable mortality has also increased, with pre-2000 esti-
mates of 1.5% mortality increasing to between 4.5% and 5.7% in recent endemic periods [9].
There are standardised guidelines for controlling CDI [11] however, they are strategy-level,
not particularly prescriptive and tend to be reactive. There are many infection control inter-
vention options available to reduce transmission and most hospitals employ a mixed approach
that combines antimicrobial stewardship, hand hygiene, environmental cleaning and fecal bac-
teriotherapy. There is paucity of economic evidence to support existing practice, with the
majority of guidelines built solely on clinical evidence, with no consideration of the costs and
health returns from alternative strategies of infection c0ntrol. Scarce resources for infection
prevention should be used first in those programmes that deliver the greatest health returns
per dollar invested [12–13]. The aim of this paper is to provide useful evidence for healthcare
decision-makers about the cost-effectiveness of competing investments for prevention and for
control of CDI.
Methods
Although conducted for an Australian hospital setting, methods described here can easily be
transferred to alternative settings. A hospital system perspective has been adopted for this eval-
uation, meaning that costs relating to treatment, administration, in-hospital resource use, the
monitoring of and treatment of adverse events have been included. Personal costs, such as
out-of-pocket medication, transportation, lost income or co-payment for follow-up care, have
not been included.
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Model structure
A decision analytic model was developed to evaluate the cost-effectiveness of interventions
that reduce CDI [14]. Given the chronic and repetitive nature of the disease, the model needed
to be state-based and able to include recursive events. A Markov model was developed based
on the natural history of the disease and data from Australian hospitals. The model depicts the
movement of adult patients through numerous health states over time, with each health state
having a cost and health utility weight attached to time spent in that state. This structure pro-
vides the framework for the evaluation and is used to estimate the costs and health outcomes
associated with each intervention. The model (Fig 1) includes two absorbing states–‘death’ and
‘censored’. Patients are censored when their timeline reaches the limit of the available data,
which was collected over an 18-month period. For example, we used observed data on those
who were discharged from hospital in a vulnerable state and did not return to hospital during
the length of available follow-up time, but who may have returned if we had a longer follow-
up time. Death can occur from any health state, except censored. This model only applies to
healthcare-associated infection and does not include infections that have been imported to
the hospital from the community. As such, all patients begin in the health state ‘at-risk’ and
represent newly admitted patients. Patients can either remain in the ‘at-risk’ state or transition
into one of three states: ‘non-severe infection’, ‘severe infection’ or ‘discharged healthy’. It is
assumed that there is no possibility of movement between the two infective states. Patients
who suffer an infection ultimately leave the system only either in the state ‘discharged vulnera-
ble 1’ or ‘death’. All patients who have suffered infection are classified as ‘vulnerable’ due to
the damage done to the gut’s microbiota and their exposure to antibiotics during treatment.
Patients in the state ‘discharged vulnerable 1’ can remain in this state, experience a recurrence
and move to ‘recurrent infection’, or enter either absorbing state. Due to a lack of data clarity,
recurrent patients could not be categorised according to disease severity, so we assumed that
all recurrent infections were severe. Patients who have a recurrent infection are transitioned
from their infective category to a vulnerable state—‘discharged vulnerable 2’—or one of the
absorbing states. Patients who are ‘discharged vulnerable 2’ but who avoid another infection
recurrence or death will eventually transition to ‘censored’. The model structure emerged
from consultations with infection control nurses and infectious disease physicians to ensure it
resembles reality.
Interventions included in the evaluation
All strategies were compared with ‘standard care’, which was assumed to be: a current antimi-
crobial stewardship programme or antimicrobial restriction policy (AMS), a hand hygiene and
environmental cleaning programme for the whole hospital, and the capacity to undertake fecal
microbiota transplant (FMT). Rates consistent with those previously published were used [15]:
the baseline level of antimicrobial exposure in a hospital at any given time was assumed to be
50% of inpatients [16–17]; the average time for gut flora to be properly restored was 90 days
post-infection [18]; and the average length of stay for all hospitalised patients was assumed to
be 5.8 days [19].
The interventions considered are described in Table 1. A panel of experienced infection
control clinicians screened all interventions for clinical plausibility and practicality, with inter-
vention bundles being included to reflect the reality of practice in service delivery [20]. A prag-
matic approach was taken when choosing which interventions were included in the final
analysis. This was especially important when considering bundled interventions, with only
those that were deemed to be realistically plausible included, to minimise the likelihood of
overestimating transmission reduction. In addition, some possible bundle combinations, such
The economics of C. difficile infection
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Fig 1. Pictorial representation of the Markov model used to estimate costs and QALYs for patients with C.
difficile.
https://doi.org/10.1371/journal.pone.0190093.g001
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as AMS and FMT, were deliberately omitted due to their clinical implausibility. This model is
a flexible framework for the evaluation of numerous infection control strategies and includes a
range of efficacy estimations for each intervention, based on published estimates. The inclu-
sion of a range of efficacy estimates represents modelled changes to C. difficile transmission
rates and shows the range of results that may be achievable under certain local conditions. The
research team is happy to share the full model on an open access platform for others to evalu-
ate other strategies, or different strategy efficacy levels that are not explicitly shown in these
results and has made all input parameter information available in text and within supporting
information files.
Hygiene improvement (HYG) is a combination of two fundamental infection control strate-
gies–hand hygiene and environmental cleaning. Hand hygiene programmes are part of routine
hospital infection control practice and the efficacy of environmental cleaning is presented
elsewhere [11;21]. Antimicrobial stewardship (AMS) is a common intervention that targets a
major risk factor in C. difficile transmission–the overuse of antibiotics. AMS programmes are
designed to encourage more careful and controlled prescribing practices, to improve patient
outcomes and limit antibiotic associated disease and resistance [22–23]. The effectiveness of
AMS programmes has been the subject of debate, with achievable reduction in antimicrobial
use being reported to range from 5% to 60% [24–25]. Fecal microbiota transplant (FMT) is
where a stool sample from a non-infected donor is transplanted into the infected patient in
an attempt to restore their normal gut microbiota. Whilst not commonly thought of as a
Table 1. Interventions included in cost-effectiveness analysis.
Intervention
(Modelled Change)
Description
AMS 1
(Large Reduction)
An antimicrobial stewardship programme that reduces antibiotic use
across the hospital such that patients in the vulnerable category are
reduced from 50% to 25% (best reported reduction attributed to AMS
programmes)
AMS 2
(Moderate Reduction)
An antimicrobial stewardship programme that reduces antibiotic use
across the hospital such that patients in the vulnerable category are
reduced from 50% to 40% (average reported reduction attributed to AMS
programmes)
HYG 1
(Large Reduction)
A hygiene improvement intervention that has the effect of reducing the
transmission rate by half
HYG 2
(Moderate Reduction)
A hygiene improvement intervention that has the effect of reducing the
transmission rate by a quarter
FMT 1
(Moderate Reduction)
Expedited gut recovery due to FMT for infected patients (time to recovery
halved– 45 days)
FMT 2
(Large Reduction)
Expedited gut recovery due to FMT for infected patients (best reported
recovery rate– 10 days)
FMT 3
(Conservative Reduction)
Expedited gut recovery due to FMT for infected patients (worst reported
recovery rate– 62 days)
AMS & HYG
(Moderate AMS, Large HYG
Reduction)
An antimicrobial stewardship programme and hygiene improvement
programme delivered as a bundle (reduction in antibiotic use from 50% to
40% of patients; transmission rate halved due to effectiveness of hygiene
improvement programme)
HYG & FMT 1
(Moderate FMT, Large HYG
Reduction)
A hygiene improvement programme delivered in conjunction with FMT
for recurrently infected patients (gut recovery time halved due to FMT;
transmission rate halved due to effectiveness of hygiene improvement
programme)
HYG & FMT 2
(Large FMT, Large HYG
Reduction)
A hygiene improvement programme delivered in conjunction with FMT
for recurrent patients (best reported gut recovery rate due to FMT;
transmission rate halved due to effectiveness of hygiene improvement
programme)
https://doi.org/10.1371/journal.pone.0190093.t001
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traditional infection control intervention, there is growing evidence that FMT is particularly
effective in treating recurrent infections [26]. Health services can utilise FMT as a transmis-
sion-inhibiting intervention as its successful implementation as a therapeutic option will limit
in-hospital transmission from recurrent patients.
Data sources
The model is populated with data from a range of sources (Table 2). The estimation of inter-
vention cost followed a published framework of identifying, measuring and valuing resources;
to record only the expenditure required to produce a health effect [27]. Inventories detailing
the resources required to physically run each intervention in a real-world hospital were devel-
oped and can be made available by request, enabling this study’s method to be tailored for dif-
ferent health systems around the world. A microcosting approach was taken to value the
medical resources required for all interventions in 2015 Australian dollars. Microcosting
includes detailing all inputs used in the treatment of a particular patient [28]. Non-medical
resources, such as staff time, were estimated using data from the Queensland Department of
Health’s human resources department. The estimation of infection-related costs was catego-
rised by diagnosis costs, treatment costs and valuation of bed-days lost to CDI. Diagnosis costs
included all costs incurred by the healthcare system when identifying and confirming the pres-
ence of infection. Only the cost of the most common treatment regimens was included in the
analysis, with specialty regimens or rarely used drugs deliberately omitted. Treatment regi-
mens for all infected states were informed by the Australasian Society of Infectious Diseases
guidelines for treatment and costs were informed by the Australian Pharmaceutical Benefits
Scheme (PBS) [29]. The value of ICU-bed and ward-bed days was informed by published esti-
mates [30–31] and different methods for valuing bed days in monetary terms was explored in
scenario analysis.
The rate that patients move between compartments in the model was informed by a hospi-
tal morbidity dataset provided by the Western Australian Department of Health data linkage
branch, which contained detailed demographic and clinical information for all admitted
patients in the 18-months between 1 July 2011 and 31 December 2012. Those with an ICD-10
code for CDI (AO4.7) were extracted and examined in further detail. There were 844 C. diffi-
cile infections identified when non-severe (749) and severe (95) cases were combined. Patients
who suffered an infection but did not require a stay in ICU were assumed to suffer ‘non-severe’
illness and patients who had an infection and a concurrent stay in ICU were classified as suf-
fering ‘severe’ illness. Patients who experienced more than one hospitalisation due to the infec-
tion were tracked according to a non-identifiable patient code and these data informed the
probability of recurrent infection. Patients whose cause of death included the ICD-10 code for
C. difficile infection were used to inform the probability of dying from all of the infected health
states. The probability of dying from the ‘discharged healthy’ state was estimated using data
from Australian life tables, published by the AIHW [32]. Utility weights were assigned to all
health states in the model, with weights reflecting a preference-based valuation of the health
state, relevant to the patient’s infection status. Where possible, health utility weights were
based on estimates from published studies. Expert opinion was used for those health states that
could not be informed from the literature. The quality of the evidence used to populate the
model was assessed according to published criteria described by Cooper et al [33]. The param-
eters included in the economic model are in Table 2.
The best available evidence was used in the study, but due to typical limitations in availabil-
ity and access it was obtained from a range of sources, both within Australia and from pub-
lished work outside the Australian setting.
The economics of C. difficile infection
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Table 2. Input variables for the Markov model.
Variable Fixed Value Range Distribution Reference
Health Utilities (Daily)
At-Risk 0.92 0.84–0.96 Uniform [34]
Non-Severe 0.82 0.72–0.93 Uniform [34]
Severe 0.71 0.50–0.72 Uniform [34]
Discharged Vulnerable 1 0.85 0.75–0.90 Uniform [35]
Recurrent Infection 0.61 0.50–0.72 Uniform [35]
Discharged Vulnerable 2 0.80 0.70–0.85 Uniform [35]
Discharged Healthy 0.88 0.84–0.92 Uniform [36]
Costs ($AUD) ($AUD)
Diagnosis (Non-Severe) $58.48 $52.63-$64.33 Uniform [37]
Diagnosis (Severe) $29.24 $26.32-$32.16 Uniform [37]
Diagnosis (Recurrent Inf) $16.08 $14.48-$17.69 Uniform [37]
Hospital (Non-Severe) $800 $720-$880 Uniform [38]
Hospital (Severe) $3000 $2700-$3300 Uniform [38]
Hospital (Recurrent Inf) $1900 $1710-$2090 Uniform [38]
Treatment (Non-Severe) $3.71 $3.34-$4.08 Uniform [29]
Treatment (Severe) $47.43 $42.69-$52.17 Uniform [29]
Treatment (Recurrent Inf) $99.69 $89.72-$109.66 Uniform [29]
Transition Probabilities (alpha; beta)
At-risk to:
Remain at-risk 0.273 (236461; 629636) Beta [39]
Non-severe 0.0001 (93; 866004) Beta [39]
Severe 4.61E-06 (4; 866093) Beta [39]
Discharged healthy 0.725 (628408; 237689) Beta [39]
Dead 0.001 (1131; 864966) Beta [32]
Non-severe infection to:
Remain non-severe 0.752 (70; 23) Beta [39]
Dead 0.000 (0.1; 93.1) Beta [39]
Discharged vulnerable 1 0.247 (23; 70) Beta [39]
Severe infection to:
Remain severe 0.75 (3; 1) Beta [39]
Dead 0.000 (0.1; 4.1) Beta [39]
Discharged vulnerable 1 0.25 (1; 3) Beta [39]
Discharged vulnerable 1 to:
Remain discharged vulnerable 1 0.829 (85; 632) Beta [39]
Censored 0.012 (1.3; 715.7) Beta [39]
Recurrent infection 0.110 (11.3; 705.7) Beta [39]
Dead 0.047 (4.9; 712.1) Beta [39]
Discharged vulnerable 2 to:
Remain discharged vulnerable 2 0.846 (22.9; 166.1) Beta [39]
Censored 0.021 (0.6; 188.4) Beta [39]
Recurrent infection 0.126 (3.4; 185.6) Beta [39]
Dead 0.005 (0.1; 188.9) Beta [39]
Recurrent infection to:
Remain recurrent infection 0.671 (19.3; 181.7) Beta [39]
Dead 0.059 (1.71; 199) Beta [39]
Discharged vulnerable 2 0.268 (7.7; 193.3) Beta [39]
Discharged healthy to:
(Continued )
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Estimating intervention effectiveness
The clinical effectiveness of each intervention was estimated from the results of a previously
published, stochastic transmission model, which assessed the increase or decrease in C. difficile
transmission as a result of that intervention [20]. Efficacy evidence was synthesised from six
studies and was used to inform the effectiveness of both bundled approaches and stand-alone
interventions. Hygiene improvement was found to have a large effect in decreasing disease inci-
dence on its own (3.2 per 1000 bed days to 1.1 per 1000 bed days), but when coupled with
another intervention, such as antimicrobial stewardship, little additional benefit was gained
(2.7 per 1000 bed days to 2.3 per 1000 bed days). Meagre reduction in C. difficile incidence was
observed for Antimicrobial stewardship (2.8 per 1000 bed days to 2.3 per 1000 bed days). Fecal
transplant was found to be an ineffective control tool on its own (2.5 per 1000 bed days to 2.4
per 1000 bed days) and in combination with other transmission reduction strategies, such as
hygiene improvement, there did not appear to be any collective effect (2.5 per 1000 bed days to
2.8 per 1000 bed days).
Estimating cost-effectiveness
The cost-effectiveness of each intervention is shown by the incremental cost-effectiveness ratio
(ICER), which is the change in costs divided by the change in health outcomes between the
intervention and the comparator of standard care. Changes in health outcomes were estimated
by combining information about intervention effectiveness and its subsequent impact on qual-
ity of life. Interventions that reduced C. difficile transmission compared with standard care had
a flow-on reduction in the total number of infections, which resulted in a decreased number of
patients who spent time in a state of reduced health. The total change in health outcomes was
expressed in terms of quality-adjusted life years (QALYs). Changes in total costs were esti-
mated by measuring total infection-related costs for standard care and each intervention.
Infection-related costs are a combination of diagnosis, treatment and hospital bed-costs. The
accrual of costs is linked to the number of infections that occur when one intervention is in
place compared to another, and as seen in Table 2, differ according to infection severity due to
disparities in treatment routine and hospital-bed costs. The incremental cost of running each
intervention, compared with standard care, was also included when estimating the change to
total costs.
Practical issues with using the ICER for decision-making exist, given that using the ratio of
two numbers has awkward statistical properties [40]. In order to simplify this ratio informa-
tion to a single number, the net monetary benefit (NMB) framework is used. Results are con-
verted from the ICER to a net monetary benefit value, through the linear rearrangement of the
ICER equation, as follows:
NMB ¼ ðWTP threshold x Change in EffectsÞ   Change in Costs
The interpretation of cost-effectiveness becomes particularly simple using the NMB: a positive
NMB indicates that a strategy is cost-effective and a negative NMB indicates that a strategy is
not cost-effective. Using the net benefit framework gives decision-makers a clear comparison
Table 2. (Continued)
Variable Fixed Value Range Distribution Reference
Health Utilities (Daily)
Remain discharged healthy 0.999 (847653; 88) Beta [39]
Dead 0.0001 (9.4; 623113) Beta [39]
https://doi.org/10.1371/journal.pone.0190093.t002
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of multiple interventions as choosing the optimal intervention is as simple as selecting the
intervention that provides the highest mean net monetary benefit. A willingness to pay of
$42,000/QALY was used as the decision-making threshold for all analyses, which is in line
with published estimates for cost-effectiveness in the Australian setting [41]. A lifetime time
horizon has been used for this evaluation and as per previously published guidelines; future
costs and health outcomes were both discounted at 5% per annum [42].
Results
Fixed value results
Fixed value analysis does not account for any uncertainty in the decision. The results in
Table 3 and Fig 2 show that of the ten interventions included, three were not cost-saving
(HYG 2, FMT 1 & FMT 3). Hygiene improvement 1 (HYG 1) achieved the greatest health ben-
efits (127 QALYs gained) and the lowest costs (over $2 million saved). Without consideration
of uncertainty, HYG 1 dominated all other interventions because it has the greatest costs saved
and health benefits gained.
Probabilistic results
Parameter uncertainty was accounted for by using Monte Carlo simulation. In order to
account for uncertainty in the model’s parameters, 10 000 simulations of the model were
made, where in each replication a value randomly drawn from each parameter’s distribution
was chosen. Table 2 shows the distributions that were applied to each of the model’s parame-
ters. At a threshold level of $42,000 per QALY gained, HYG 1 provided the highest mean
NMB ($7.5 million). The bundled approach of AMS/HYG delivered the next highest mean
NMB ($7.3 million) and AMS 1 provided the lowest mean NMB of all interventions ($15,000).
Fig 3 shows the results of the NMB analysis for all interventions. The intervention with the
highest mean NMB is deemed to be the optimal decision and should be considered for adop-
tion ahead of the other interventions [43].
Scenario analysis
Uncertainties in other aspects of the evaluation also exist and are explored through scenario
analyses. Different clinical scenarios were examined, where key parameters of the model were
altered. The modified scenarios reflected plausible situations and test the robustness of the
Table 3. Incremental outcomes of all interventions compared to standard care.
Intervention Incremental Outcomes ICER
Costs QALYs
Standard Care - - Dominated
AMS 1 -$21,145 -0.09 Dominated
AMS 2 -$381,142 5.59 Dominated
HYG 1 -$2,137,843 126.68 Cost-saving
HYG 2 $818,790 102.11 Dominated
FMT 1 $119,595 107.87 Dominated
FMT 2 -$151,146 109.91 Dominated
FMT 3 $162,426 103.89 Dominated
AMS & HYG -$2,052,003 125.14 Dominated
HYG & FMT 1 -$1,395,540 122.18 Dominated
HYG & FMT 2 -$1,332,211 120.73 Dominated
https://doi.org/10.1371/journal.pone.0190093.t003
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model. Four alternate scenarios were considered: (i) the method for valuing hospital-bed costs:
where accounting costs for an ICU- and ward-bed were substituted by the healthcare decision-
maker’s willingness to pay price, (ii) patient LOS was doubled, (iii) mortality rate was doubled
-$2,250,000
-$1,750,000
-$1,250,000
-$750,000
-$250,000
$250,000
$750,000
-1 19 39 59 79 99 119 139
Δ QALYs
Δ Costs
AMS 1
AMS 2
Hyg 1
Hyg 2
FMT 1
FMT 2
FMT 3
AMS & HYG
FMT & HYG 1
FMT & HYG 2
Standard Care
Fig 2. Incremental cost-effectiveness of interventions designed to reduce CDI.
https://doi.org/10.1371/journal.pone.0190093.g002
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Fig 3. Net Monetary Benefits at a threshold of $42,000/QALY. Means and range of values for each intervention.
https://doi.org/10.1371/journal.pone.0190093.g003
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to simulate serious outbreak conditions and, (iv) infection transmission rate was increased to
simulate differences that may exist across the Australian setting. The results of scenario analy-
ses are summarised in Table 4.
Hygiene improvement 1 (HYG 1) was optimal in most scenarios–when bed day cost was
altered, LOS was increased and when mortality rate was increased. Only when the infection
rate was increased was another intervention optimal. In this scenario the AMS/HYG bundled
intervention provided the highest mean NMB. The scenario with the greatest certainty, indi-
cated by error probability, was when the infection rate was increased. In this scenario the
probability of incorrectly choosing the AMS/HYG bundle as optimal was 0.56. The error prob-
abilities relating to the other scenarios were all high– 0.64 for scenarios 2 and 4 and 0.74 for
scenario 1. This means that despite being the intervention that provided the highest NMB, the
decision regarding HYG 1 as being optimal in multiple scenarios is highly uncertain.
Discussion
Hospitals in Australia have access to multiple infection control interventions in the quest
to reduce CDI. These results show the majority of interventions resulted in health improve-
ments, indicated by QALYs gained. QALY gains were driven by a reduction in the number of
infected patients as a result of a successful intervention, when compared with the number of
infected patients who existed under the comparator. The results also showed that bundled
interventions, as opposed to stand-alone interventions, offer the best opportunity for health
improvements. Three out of the four highest-ranking interventions in terms of highest
expected QALY gains were all bundles. The findings show that if decision-makers did not
adopt any of the proposed interventions, improvements in health outcomes and cost savings
would be forgone. If decisions are not made about the expenditure of scarce health resources,
which includes decisions about disinvesting in initiatives that are not cost-effective, increased
expenditure for no health outcome gain is probable.
The findings from model-based evaluations are always dependent on the assumptions
made. Exclusions and simplifications are not uncommon limitations and this study was no
different. There were limitations on how transition probabilities were estimated as well as limi-
tations regarding the accuracy with which hospital-acquired and community-acquired infec-
tions are described due to cross-jurisdictional differences in data collection. The estimation
of quality of life utility weights was not possible from primary data for all health states in the
model and estimating costs is a difficult process, especially when they are not routinely col-
lected at the hospital level for research purposes. Finally, the choice of interventions for inclu-
sion in the project was deliberately simplified and did not include all possible C. difficile-
related interventions. However, no economic evaluation of CDI has been undertaken in this
Table 4. Optimal intervention given different clinical scenarios ($42,000/QALY threshold).
Scenario Intervention
(Error probability)
Incremental Outcomes Mean NMB
(95% CI)
QALYs Costs Saved
1. WTP cost for bed days HYG 1
(0.74)
124.6 $535,723 $5,770,401
($5,678,579–$5,862,224)
2. Increased LOS HYG 1
(0.64)
123.8 $2,138,438 $7,337,386
($7,238,532–$7,436,241)
3. Increased infection rate AMS/HYG bundle
(0.56)
164.6 $4,692,889 $11,605,010
($11,480,838–$11,729,183)
4. Increased mortality rate HYG 1
(0.64)
127.9 $2,026,338 $7,398,668
($7,295,752–$7,501,586)
https://doi.org/10.1371/journal.pone.0190093.t004
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setting, making the findings an important addition to existing clinical knowledge. Modelling
studies also have noteworthy strengths–no prospective randomised control trial could be
designed and commissioned to compare multiple interventions side-by-side, resulting in prac-
tical information for decision-makers. The majority of the data used to inform the results was
derived from local sources, making the results very applicable to the Australian setting. Finally,
the methods that have been used in this study are transparent, reproducible and follow pub-
lished standards for this type of evaluation.
Prior to this research, Australian decision-makers have had limited access to economic evi-
dence to inform their decision-making about managing risk of CDI. Although there is uncer-
tainty in the results of this evaluation, doing nothing to change the management approach
relating to C. difficile is a decision in itself that should be weighed up with appropriate consid-
eration. Decision-makers need to understand that remaining with the status quo–simply
maintaining one’s current or previous position—is itself an explicit decision. Put simply, if
investments are not made in interventions that clearly yield gains in health outcomes com-
pared to the status quo, the allocation and use of scarce healthcare resources is inappropriate.
Limitations
Our study has limitations. The model does not account for epidemiologic parameters relating
to CDI, such as the possibility of being admitted with infection. This is due to the issue that
exists in the way that CDI is classified and reported in Australia. The definition of what consti-
tutes an infection is well known and easily accessible [44], but there remain concerns about the
accuracy with which hospital-acquired and community-acquired infections are described as
there is bound to be some overlap between genuine hospital-acquired infections and commu-
nity-acquired infections that are diagnosed and confirmed during a hospital stay. The absence
of individual clinical test results meant that the classification of illness severity was simplified.
For this project, it was assumed that the patients who had a confirmed case of infection and a
parallel stay in ICU suffered severe infection and those who did not were classified as non-
severe. This assumption may have resulted in an overestimation of severe cases, which could
have had an effect on the results. Estimation of intervention efficacy was derived from the syn-
thesis of a variety of evidence sources, which is typical for this type of evaluation. The particu-
lar estimates used in the model and presented here have been informed by the literature but
are by no means definitive. As further evidence becomes available, the model can be updated
and adapted to incorporate this.
Finally, given that the results were produced using predominantly Australian data, they are
primarily intended for the Australian setting. However, the structure of the study is based on a
flexible and adaptable Markov model, allowing inputs from newly identified literature or dif-
ferent healthcare settings to be included, making the results more appropriate for local settings
in other jurisdictions around the world. This flexibility also extends to the capacity to include
other interventions that exist to reduce C. difficile transmission in the hospital setting, if they
are deemed more locally relevant than those presented here.
Comparison to existing literature
There is little knowledge around the world about the cost of C. difficile from an economic per-
spective. Since 2014, there have been three economic evaluations published that focus on the
cost-effectiveness of fecal microbiota transplant (FMT) in different settings [36;45–46]. All
three studies found that FMT was a cost-effective approach to treating recurrent infection but
none explored FMT as a method for inhibiting transmission of the pathogen. Nowak et al.
undertook a study on the economic impact of an antimicrobial stewardship programme, but
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its focus was not solely on Clostridium difficile infection and included other HAIs–vancomy-
cin-resistant enterococci (VRE) and Methicillin-resistant Staphylococcus aureus (MRSA) in the
analysis [22]. The results are not specific to C. difficile and are not optimal for decision-making
purposes. Nelson et al. conducted an economic evaluation of six different interventions in the
USA-setting and found that implementing infection control bundles is more cost-effective
than stand-alone interventions, which supports our findings [36].
Conclusion
Until now, economic evidence relating to CDI has not been available for the Australian setting.
The findings of this evaluation should be considered together with other relevant information
that is appropriate at a local level, such as clinical outcomes, budget constraints and treatment
priorities. The results support further investment in infection control interventions, providing
evidence that such investment is an efficient use of scarce resources as cost-effective outcomes
are likely to be realised.
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